Background. Thirty to forty percent of @entity1 with high grade nonmuscle invasive @entity150 (NMIBC) fail to respond to intravesical therapy with bacillus Calmette-Guerin (BCG). Interferon-a2B plus BCG has been shown to be effective in a subset of @entity1 with NMIBC BCG refractory disease. Here we present a contemporary series on the effectiveness and safety of intravesical BCG plus interferon-a2B therapy in @entity1 with BCG refractory NMIBC. Methods. From January of 2005 to April of 2014 we retrospectively found 44 @entity1 who underwent induction with combination IFN/BCG for the management of BCG refractory NMIBC. A chart review was performed to assess initial pathological stage/grade, pathological stage/grade at the time of induction, time to IFN/BCG failure, pathological stage/grade at failure, postfailure therapy, and current disease state. Results. Of the 44 @entity1 who met criteria for the analysis. High risk disease was found in 88.6% of @entity1 at induction. The 12-month and 24-month recurrence-free survival were 38.6% and 18.2%, respectively. 25 (56.8%) ultimately had disease recurrence. Radical cystectomy was performed in 16 (36.4%) @entity1 . Conclusion. Combination BCG plus interferon-a2B remains a reasonably safe alternative treatment for select @entity1 with BCG refractory disease prior to proceeding to radical cystectomy.

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']
@entity150 :: (MESH:D001749,Disease) :: ['Bladder Cancer']
